Interplay of priors and skeletons in two-stage continual reassessment method

Statistics in Medicine

Volumn 31, Issue 30, 2012, Pages 4321-4336

  Iasonos, Alexia ^a   O'Quigley, John ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

Continual reassessment method; Dose finding; Informative; Phase I; Two stage designs

Indexed keywords

ACCURACY; ARTICLE; CONTINUAL REASSESSMENT METHOD; INTERMETHOD COMPARISON; MAXIMUM LIKELIHOOD METHOD; MAXIMUM TOLERATED DOSE; SIMULATION; STATISTICAL MODEL; STUDY DESIGN;

BAYES THEOREM; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; HUMANS; LIKELIHOOD FUNCTIONS; MAXIMUM TOLERATED DOSE; MODELS, STATISTICAL; RESEARCH DESIGN;

EID: 84870938147     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.5559     Document Type: Article

References (27)

1. Iasonos A, Wilton AS, Riedel ER, Seshan VE, Spriggs DR. A comprehensive comparison of the continual reassessment method to the standard 3+3 dose escalation scheme in phase I dose-finding studies. Clinical Trials 2008; 5:465-477.
2. Su Z. A two-stage algorithm for designing phase I cancer clinical trials for two new molecular entities. Contemporary Clinical Trials 2010; 31(1):105-107. Epub 2009 Oct 30.
3. Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. Journal of National Cancer Institute 2009; 101(10):708-720.
4. Iasonos A, Zohar S, O'Quigley J. Incorporating lower grade toxicity information into dose finding designs clinical trials. Clinical Trials 2011; 8:370-379.
5. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics 1990; 46:33-48.
6. O'Quigley J, Shen LZ. Continual reassessment method: a likelihood approach. Biometrics 1996; 52:673-684.
7. Whitehead J, Williamson D. Bayesian decision procedures based on logistic regression models for dose-finding studies. Journal of Biopharmaceutical Statistics 1998; 8:445-467.
8. O'Quigley J, Iasonos A, Crowley J. Dose-finding designs based on the continual reassessment method, Chapter 2. In Handbook of Statistics in Clinical Oncology, (3rd edn.). Crowley J, Hoering A (eds). Chapman and Hall/CRC: London, 2011; 21-52.
9. Cheung YK. Coherence principles in dose-finding studies. Biometrika 2005; 92:863-873.
10. O'Quigley J, Zohar S. Retrospective robustness of the continual reassessment method. Journal of Biopharmaceutical Statistics 2010; 20(5):1013-1025.
11. Lee SM, Cheung YK. Model calibration in the continual reassessment method. Clinical Trials 2009; 6(3):227-238.
12. Daimon S, Zohar S, O'Quigley J. Posterior maximization and averaging for Bayesian working model choice in the continual reassessment method. Statistics in Medicine 2011; 30(13):1563-1573.
13. O'Quigley J. Theoretical study of the continual reassessment method. Journal of Statistical Planning and Inference 2006; 136(6):1765-1780.
14. Morita S, Thall PF, Mller P. Determining the effective sample size of a parametric prior. Biometrics Jun 2008; 64(2):595-602.
15. Moller S. An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses. Statistics in Medicine 1995; 14(9):911-922.
16. Yin G, Yuan Y. Bayesian model averaging continual reassessment method in phase I clinical trials. Journal of the American Statistical Association 2009; 104(487):954-968.
17. Iasonos A, Ostrovnaya I. Estimating the dose-toxicity curve in completed phase I studies. Statistics in Medicine 2011; 30(17):2117-2129.
18. O'Quigley J, Zohar S. Experimental designs for phase I and phase I/II dose-finding studies. British Journal of Cancer 2006; 94:609-613.
19. He W, Liu J, Binkowitz B, Quan H. A model-based approach in the estimation of the maximum tolerated dose in phase I cancer clinical trials. Statistics in Medicine 2006; 25(12):2027-2042.
20. O'Quigley J. Retrospective analysis of sequential dose-finding designs. Biometrics 2005; 61(3):749-756.
21. Cheung YK, Chappell R. A simple technique to evaluate model sensitivity in the continual reassessment method. Biometrics 2002; 58(3):671-674.
22. Resche-Rigon M, Zohar S, Chevret S. Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomes. Clinical Trials 2008; 5(6):595-606.
23. Resche-Rigon M, Zohar S, Chevret S. Maximum-relevance weighted likelihood estimator: application to the continual reassessment method. Statistics and its Interface 2010; 3(2):177-184.
24. Le Tourneau C, Stathis A, Vidal L, Moore MJ, Siu LL. Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials. Journal of Clinical Oncology 2010; 28(8):1401-1407. Review.
25. Zohar S, Chevret S. Phase I (or phase II) dose-ranging clinical trials: proposal of a two-stage Bayesian design. Journal of Biopharmaceutical Statistics 2003; 13(1):87-101.
26. Morita S, Thall P, Muller P. Evaluating the impact of prior assumptions in Bayesian biostatistics. Statistics in Biosciences 2010; 2(1):1-17.
27. Ivanova A, Flournoy N. Comparison of isotonic designs for dose-finding. Statistics in Biopharmaceutical Research 2009; 1:101-107.